nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Carmustine—lymphatic system cancer	0.259	1	CbGbCtD
Anagrelide—Urethral disorder—Vincristine—lymphatic system cancer	0.00135	0.00182	CcSEcCtD
Anagrelide—Eye disorder—Carmustine—lymphatic system cancer	0.00135	0.00182	CcSEcCtD
Anagrelide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00135	0.00182	CcSEcCtD
Anagrelide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00134	0.00181	CcSEcCtD
Anagrelide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00134	0.00181	CcSEcCtD
Anagrelide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00134	0.00181	CcSEcCtD
Anagrelide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00133	0.0018	CcSEcCtD
Anagrelide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00133	0.00179	CcSEcCtD
Anagrelide—Anaemia—Bleomycin—lymphatic system cancer	0.00133	0.00179	CcSEcCtD
Anagrelide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00132	0.00178	CcSEcCtD
Anagrelide—Asthenia—Teniposide—lymphatic system cancer	0.00131	0.00176	CcSEcCtD
Anagrelide—Melaena—Methotrexate—lymphatic system cancer	0.0013	0.00175	CcSEcCtD
Anagrelide—Malaise—Bleomycin—lymphatic system cancer	0.0013	0.00175	CcSEcCtD
Anagrelide—Pruritus—Teniposide—lymphatic system cancer	0.00129	0.00174	CcSEcCtD
Anagrelide—Arrhythmia—Carmustine—lymphatic system cancer	0.00129	0.00174	CcSEcCtD
Anagrelide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00128	0.00172	CcSEcCtD
Anagrelide—Alopecia—Carmustine—lymphatic system cancer	0.00127	0.00172	CcSEcCtD
Anagrelide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00126	0.00171	CcSEcCtD
Anagrelide—Malnutrition—Carmustine—lymphatic system cancer	0.00125	0.00169	CcSEcCtD
Anagrelide—Cough—Bleomycin—lymphatic system cancer	0.00125	0.00169	CcSEcCtD
Anagrelide—Diarrhoea—Teniposide—lymphatic system cancer	0.00125	0.00168	CcSEcCtD
Anagrelide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00124	0.00167	CcSEcCtD
Anagrelide—Chest pain—Bleomycin—lymphatic system cancer	0.00122	0.00165	CcSEcCtD
Anagrelide—Myalgia—Bleomycin—lymphatic system cancer	0.00122	0.00165	CcSEcCtD
Anagrelide—Alopecia—Vincristine—lymphatic system cancer	0.00122	0.00164	CcSEcCtD
Anagrelide—Back pain—Carmustine—lymphatic system cancer	0.00121	0.00164	CcSEcCtD
Anagrelide—Discomfort—Bleomycin—lymphatic system cancer	0.00121	0.00163	CcSEcCtD
Anagrelide—Chills—Mitoxantrone—lymphatic system cancer	0.0012	0.00162	CcSEcCtD
Anagrelide—Ecchymosis—Methotrexate—lymphatic system cancer	0.0012	0.00162	CcSEcCtD
Anagrelide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.0012	0.00161	CcSEcCtD
Anagrelide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00118	0.0016	CcSEcCtD
Anagrelide—Confusional state—Bleomycin—lymphatic system cancer	0.00118	0.00159	CcSEcCtD
Anagrelide—Vision blurred—Carmustine—lymphatic system cancer	0.00118	0.00159	CcSEcCtD
Anagrelide—Oedema—Bleomycin—lymphatic system cancer	0.00117	0.00158	CcSEcCtD
Anagrelide—Infection—Bleomycin—lymphatic system cancer	0.00117	0.00157	CcSEcCtD
Anagrelide—Anaemia—Carmustine—lymphatic system cancer	0.00116	0.00156	CcSEcCtD
Anagrelide—Back pain—Vincristine—lymphatic system cancer	0.00116	0.00156	CcSEcCtD
Anagrelide—Vomiting—Teniposide—lymphatic system cancer	0.00116	0.00156	CcSEcCtD
Anagrelide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00115	0.00155	CcSEcCtD
Anagrelide—Asthenia—Fludarabine—lymphatic system cancer	0.00115	0.00155	CcSEcCtD
Anagrelide—Rash—Teniposide—lymphatic system cancer	0.00115	0.00155	CcSEcCtD
Anagrelide—Dermatitis—Teniposide—lymphatic system cancer	0.00115	0.00155	CcSEcCtD
Anagrelide—Headache—Teniposide—lymphatic system cancer	0.00114	0.00154	CcSEcCtD
Anagrelide—Pruritus—Fludarabine—lymphatic system cancer	0.00113	0.00153	CcSEcCtD
Anagrelide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00113	0.00153	CcSEcCtD
Anagrelide—Back pain—Mitoxantrone—lymphatic system cancer	0.00113	0.00152	CcSEcCtD
Anagrelide—Anorexia—Bleomycin—lymphatic system cancer	0.00112	0.00151	CcSEcCtD
Anagrelide—Anaemia—Vincristine—lymphatic system cancer	0.00111	0.00149	CcSEcCtD
Anagrelide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0011	0.00148	CcSEcCtD
Anagrelide—Photosensitivity—Methotrexate—lymphatic system cancer	0.0011	0.00148	CcSEcCtD
Anagrelide—Hypotension—Bleomycin—lymphatic system cancer	0.0011	0.00148	CcSEcCtD
Anagrelide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00109	0.00148	CcSEcCtD
Anagrelide—Convulsion—Carmustine—lymphatic system cancer	0.00109	0.00147	CcSEcCtD
Anagrelide—Hypertension—Carmustine—lymphatic system cancer	0.00108	0.00146	CcSEcCtD
Anagrelide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00108	0.00146	CcSEcCtD
Anagrelide—Nausea—Teniposide—lymphatic system cancer	0.00108	0.00146	CcSEcCtD
Anagrelide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00108	0.00145	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00107	0.00144	CcSEcCtD
Anagrelide—Myalgia—Carmustine—lymphatic system cancer	0.00107	0.00144	CcSEcCtD
Anagrelide—Chest pain—Carmustine—lymphatic system cancer	0.00107	0.00144	CcSEcCtD
Anagrelide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00105	0.00142	CcSEcCtD
Anagrelide—Malaise—Mitoxantrone—lymphatic system cancer	0.00105	0.00142	CcSEcCtD
Anagrelide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00105	0.00141	CcSEcCtD
Anagrelide—Convulsion—Vincristine—lymphatic system cancer	0.00104	0.0014	CcSEcCtD
Anagrelide—Hypertension—Vincristine—lymphatic system cancer	0.00103	0.00139	CcSEcCtD
Anagrelide—Confusional state—Carmustine—lymphatic system cancer	0.00103	0.00139	CcSEcCtD
Anagrelide—Oedema—Carmustine—lymphatic system cancer	0.00102	0.00138	CcSEcCtD
Anagrelide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00102	0.00138	CcSEcCtD
Anagrelide—Myalgia—Vincristine—lymphatic system cancer	0.00102	0.00137	CcSEcCtD
Anagrelide—Cough—Mitoxantrone—lymphatic system cancer	0.00102	0.00137	CcSEcCtD
Anagrelide—Infection—Carmustine—lymphatic system cancer	0.00102	0.00137	CcSEcCtD
Anagrelide—Vomiting—Fludarabine—lymphatic system cancer	0.00102	0.00137	CcSEcCtD
Anagrelide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00101	0.00136	CcSEcCtD
Anagrelide—Rash—Fludarabine—lymphatic system cancer	0.00101	0.00136	CcSEcCtD
Anagrelide—Dermatitis—Fludarabine—lymphatic system cancer	0.00101	0.00136	CcSEcCtD
Anagrelide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00101	0.00136	CcSEcCtD
Anagrelide—Pain—Bleomycin—lymphatic system cancer	0.001	0.00135	CcSEcCtD
Anagrelide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.001	0.00135	CcSEcCtD
Anagrelide—Headache—Fludarabine—lymphatic system cancer	0.001	0.00135	CcSEcCtD
Anagrelide—Tachycardia—Carmustine—lymphatic system cancer	0.000999	0.00135	CcSEcCtD
Anagrelide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000993	0.00134	CcSEcCtD
Anagrelide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000993	0.00134	CcSEcCtD
Anagrelide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000993	0.00134	CcSEcCtD
Anagrelide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000985	0.00133	CcSEcCtD
Anagrelide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000981	0.00132	CcSEcCtD
Anagrelide—Oedema—Vincristine—lymphatic system cancer	0.000977	0.00132	CcSEcCtD
Anagrelide—Anorexia—Carmustine—lymphatic system cancer	0.000976	0.00132	CcSEcCtD
Anagrelide—Infection—Vincristine—lymphatic system cancer	0.000971	0.00131	CcSEcCtD
Anagrelide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000966	0.0013	CcSEcCtD
Anagrelide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000965	0.0013	CcSEcCtD
Anagrelide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00096	0.00129	CcSEcCtD
Anagrelide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000958	0.00129	CcSEcCtD
Anagrelide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000957	0.00129	CcSEcCtD
Anagrelide—Hypotension—Carmustine—lymphatic system cancer	0.000957	0.00129	CcSEcCtD
Anagrelide—Oedema—Mitoxantrone—lymphatic system cancer	0.000952	0.00128	CcSEcCtD
Anagrelide—Nausea—Fludarabine—lymphatic system cancer	0.00095	0.00128	CcSEcCtD
Anagrelide—Infection—Mitoxantrone—lymphatic system cancer	0.000946	0.00128	CcSEcCtD
Anagrelide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000945	0.00127	CcSEcCtD
Anagrelide—Shock—Mitoxantrone—lymphatic system cancer	0.000936	0.00126	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000933	0.00126	CcSEcCtD
Anagrelide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000932	0.00126	CcSEcCtD
Anagrelide—Urticaria—Bleomycin—lymphatic system cancer	0.000932	0.00126	CcSEcCtD
Anagrelide—Anorexia—Vincristine—lymphatic system cancer	0.000932	0.00126	CcSEcCtD
Anagrelide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000929	0.00125	CcSEcCtD
Anagrelide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000927	0.00125	CcSEcCtD
Anagrelide—Insomnia—Carmustine—lymphatic system cancer	0.000926	0.00125	CcSEcCtD
Anagrelide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000924	0.00125	CcSEcCtD
Anagrelide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00092	0.00124	CcSEcCtD
Anagrelide—Paraesthesia—Carmustine—lymphatic system cancer	0.000919	0.00124	CcSEcCtD
Anagrelide—Hypotension—Vincristine—lymphatic system cancer	0.000913	0.00123	CcSEcCtD
Anagrelide—Dyspnoea—Carmustine—lymphatic system cancer	0.000913	0.00123	CcSEcCtD
Anagrelide—Somnolence—Carmustine—lymphatic system cancer	0.00091	0.00123	CcSEcCtD
Anagrelide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000907	0.00122	CcSEcCtD
Anagrelide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000891	0.0012	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00089	0.0012	CcSEcCtD
Anagrelide—Decreased appetite—Carmustine—lymphatic system cancer	0.00089	0.0012	CcSEcCtD
Anagrelide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000889	0.0012	CcSEcCtD
Anagrelide—Insomnia—Vincristine—lymphatic system cancer	0.000884	0.00119	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000884	0.00119	CcSEcCtD
Anagrelide—Paraesthesia—Vincristine—lymphatic system cancer	0.000878	0.00118	CcSEcCtD
Anagrelide—Pain—Carmustine—lymphatic system cancer	0.000875	0.00118	CcSEcCtD
Anagrelide—Constipation—Carmustine—lymphatic system cancer	0.000875	0.00118	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000867	0.00117	CcSEcCtD
Anagrelide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000855	0.00115	CcSEcCtD
Anagrelide—Decreased appetite—Vincristine—lymphatic system cancer	0.00085	0.00115	CcSEcCtD
Anagrelide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000849	0.00114	CcSEcCtD
Anagrelide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000846	0.00114	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000844	0.00114	CcSEcCtD
Anagrelide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000844	0.00114	CcSEcCtD
Anagrelide—Fatigue—Vincristine—lymphatic system cancer	0.000843	0.00114	CcSEcCtD
Anagrelide—Asthenia—Bleomycin—lymphatic system cancer	0.000841	0.00113	CcSEcCtD
Anagrelide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000838	0.00113	CcSEcCtD
Anagrelide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000837	0.00113	CcSEcCtD
Anagrelide—Pain—Vincristine—lymphatic system cancer	0.000836	0.00113	CcSEcCtD
Anagrelide—Constipation—Vincristine—lymphatic system cancer	0.000836	0.00113	CcSEcCtD
Anagrelide—Asthma—Methotrexate—lymphatic system cancer	0.000834	0.00112	CcSEcCtD
Anagrelide—Pruritus—Bleomycin—lymphatic system cancer	0.00083	0.00112	CcSEcCtD
Anagrelide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000827	0.00112	CcSEcCtD
Anagrelide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000821	0.00111	CcSEcCtD
Anagrelide—Pancreatitis—Methotrexate—lymphatic system cancer	0.000818	0.0011	CcSEcCtD
Anagrelide—Pain—Mitoxantrone—lymphatic system cancer	0.000814	0.0011	CcSEcCtD
Anagrelide—Constipation—Mitoxantrone—lymphatic system cancer	0.000814	0.0011	CcSEcCtD
Anagrelide—Abdominal pain—Carmustine—lymphatic system cancer	0.000809	0.00109	CcSEcCtD
Anagrelide—Body temperature increased—Carmustine—lymphatic system cancer	0.000809	0.00109	CcSEcCtD
Anagrelide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000799	0.00108	CcSEcCtD
Anagrelide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000799	0.00108	CcSEcCtD
Anagrelide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000792	0.00107	CcSEcCtD
Anagrelide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000784	0.00106	CcSEcCtD
Anagrelide—Dysuria—Methotrexate—lymphatic system cancer	0.00078	0.00105	CcSEcCtD
Anagrelide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000778	0.00105	CcSEcCtD
Anagrelide—Body temperature increased—Vincristine—lymphatic system cancer	0.000773	0.00104	CcSEcCtD
Anagrelide—Abdominal pain—Vincristine—lymphatic system cancer	0.000773	0.00104	CcSEcCtD
Anagrelide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000768	0.00104	CcSEcCtD
Anagrelide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000761	0.00103	CcSEcCtD
Anagrelide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000756	0.00102	CcSEcCtD
Anagrelide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000752	0.00101	CcSEcCtD
Anagrelide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000752	0.00101	CcSEcCtD
Anagrelide—Pneumonia—Methotrexate—lymphatic system cancer	0.000748	0.00101	CcSEcCtD
Anagrelide—Vomiting—Bleomycin—lymphatic system cancer	0.000746	0.00101	CcSEcCtD
Anagrelide—Depression—Methotrexate—lymphatic system cancer	0.000741	0.001	CcSEcCtD
Anagrelide—Rash—Bleomycin—lymphatic system cancer	0.000739	0.000997	CcSEcCtD
Anagrelide—Dermatitis—Bleomycin—lymphatic system cancer	0.000739	0.000996	CcSEcCtD
Anagrelide—Asthenia—Carmustine—lymphatic system cancer	0.000735	0.000991	CcSEcCtD
Anagrelide—Renal failure—Methotrexate—lymphatic system cancer	0.000731	0.000986	CcSEcCtD
Anagrelide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000723	0.000975	CcSEcCtD
Anagrelide—Sweating—Methotrexate—lymphatic system cancer	0.000713	0.000961	CcSEcCtD
Anagrelide—Haematuria—Methotrexate—lymphatic system cancer	0.000709	0.000956	CcSEcCtD
Anagrelide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000703	0.000948	CcSEcCtD
Anagrelide—Epistaxis—Methotrexate—lymphatic system cancer	0.000701	0.000946	CcSEcCtD
Anagrelide—Asthenia—Vincristine—lymphatic system cancer	0.000701	0.000946	CcSEcCtD
Anagrelide—Diarrhoea—Carmustine—lymphatic system cancer	0.0007	0.000945	CcSEcCtD
Anagrelide—Nausea—Bleomycin—lymphatic system cancer	0.000697	0.00094	CcSEcCtD
Anagrelide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000683	0.000921	CcSEcCtD
Anagrelide—Dizziness—Carmustine—lymphatic system cancer	0.000677	0.000913	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—lymphatic system cancer	0.000671	0.000905	CcSEcCtD
Anagrelide—Diarrhoea—Vincristine—lymphatic system cancer	0.000669	0.000902	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—lymphatic system cancer	0.000667	0.0009	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—lymphatic system cancer	0.000667	0.0009	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000662	0.000893	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000659	0.000889	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000654	0.000882	CcSEcCtD
Anagrelide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000651	0.000878	CcSEcCtD
Anagrelide—Vomiting—Carmustine—lymphatic system cancer	0.000651	0.000878	CcSEcCtD
Anagrelide—Dizziness—Vincristine—lymphatic system cancer	0.000646	0.000872	CcSEcCtD
Anagrelide—Rash—Carmustine—lymphatic system cancer	0.000645	0.000871	CcSEcCtD
Anagrelide—Dermatitis—Carmustine—lymphatic system cancer	0.000645	0.00087	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—lymphatic system cancer	0.000643	0.000868	CcSEcCtD
Anagrelide—Headache—Carmustine—lymphatic system cancer	0.000641	0.000865	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—lymphatic system cancer	0.000624	0.000841	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—lymphatic system cancer	0.000622	0.000839	CcSEcCtD
Anagrelide—Vomiting—Vincristine—lymphatic system cancer	0.000621	0.000838	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000619	0.000835	CcSEcCtD
Anagrelide—Rash—Vincristine—lymphatic system cancer	0.000616	0.000831	CcSEcCtD
Anagrelide—Dermatitis—Vincristine—lymphatic system cancer	0.000616	0.00083	CcSEcCtD
Anagrelide—Headache—Vincristine—lymphatic system cancer	0.000612	0.000826	CcSEcCtD
Anagrelide—Nausea—Carmustine—lymphatic system cancer	0.000608	0.00082	CcSEcCtD
Anagrelide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000605	0.000816	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000602	0.000811	CcSEcCtD
Anagrelide—Rash—Mitoxantrone—lymphatic system cancer	0.0006	0.000809	CcSEcCtD
Anagrelide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0006	0.000809	CcSEcCtD
Anagrelide—Chills—Methotrexate—lymphatic system cancer	0.000599	0.000808	CcSEcCtD
Anagrelide—Headache—Mitoxantrone—lymphatic system cancer	0.000596	0.000804	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—lymphatic system cancer	0.00059	0.000795	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—lymphatic system cancer	0.000581	0.000784	CcSEcCtD
Anagrelide—Nausea—Vincristine—lymphatic system cancer	0.00058	0.000783	CcSEcCtD
Anagrelide—Nausea—Mitoxantrone—lymphatic system cancer	0.000565	0.000762	CcSEcCtD
Anagrelide—Back pain—Methotrexate—lymphatic system cancer	0.000562	0.000758	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—lymphatic system cancer	0.000548	0.000739	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000539	0.000727	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—lymphatic system cancer	0.000537	0.000724	CcSEcCtD
Anagrelide—Malaise—Methotrexate—lymphatic system cancer	0.000524	0.000707	CcSEcCtD
Anagrelide—Cough—Methotrexate—lymphatic system cancer	0.000507	0.000684	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—lymphatic system cancer	0.000503	0.000679	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—lymphatic system cancer	0.000495	0.000667	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—lymphatic system cancer	0.000495	0.000667	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—lymphatic system cancer	0.000495	0.000667	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000491	0.000663	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—lymphatic system cancer	0.000489	0.000659	CcSEcCtD
Anagrelide—Confusional state—Methotrexate—lymphatic system cancer	0.000478	0.000645	CcSEcCtD
Anagrelide—Infection—Methotrexate—lymphatic system cancer	0.000471	0.000635	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000465	0.000627	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000464	0.000626	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—lymphatic system cancer	0.000461	0.000621	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000458	0.000618	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—lymphatic system cancer	0.000452	0.00061	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—lymphatic system cancer	0.000443	0.000598	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000432	0.000583	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—lymphatic system cancer	0.000429	0.000578	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000426	0.000574	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000423	0.00057	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—lymphatic system cancer	0.000422	0.000569	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000417	0.000563	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000412	0.000556	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000409	0.000552	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—lymphatic system cancer	0.000409	0.000551	CcSEcCtD
Anagrelide—Pain—Methotrexate—lymphatic system cancer	0.000406	0.000547	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000391	0.000527	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000388	0.000523	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—lymphatic system cancer	0.000377	0.000508	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000375	0.000506	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000375	0.000506	CcSEcCtD
Anagrelide—Asthenia—Methotrexate—lymphatic system cancer	0.00034	0.000459	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—lymphatic system cancer	0.000335	0.000452	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000324	0.000438	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—lymphatic system cancer	0.000314	0.000423	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—lymphatic system cancer	0.000302	0.000407	CcSEcCtD
Anagrelide—Rash—Methotrexate—lymphatic system cancer	0.000299	0.000403	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—lymphatic system cancer	0.000299	0.000403	CcSEcCtD
Anagrelide—Headache—Methotrexate—lymphatic system cancer	0.000297	0.000401	CcSEcCtD
Anagrelide—Nausea—Methotrexate—lymphatic system cancer	0.000282	0.00038	CcSEcCtD
